Summary The effects of the combination of cisplatin and other cytotoxic agents were studied in vitro. When A549 lung cancer cells were treated simultaneously with cisplatin and other cytotoxic agents, cisplatin additively increased the cytotoxic effects of etoposide, mitomycinC, adriamycin, 5-fluorouracil and 1-fl-Darabinofuranosylcytosine, but antagonised those of vincristine, vindesine, vinblastine and podophyllotoxin. The antagonism between cisplatin and vincristine was also observed with HT29 colon cancer cells, NC65 renal carcinoma cells and A431 epidermoid carcinoma cells.when these cells were simultaneously exposed to both agents. When A549 cells were exposed to cisplatin and vincristine sequentially, the antagonism between them was evident when cells were pretreated with cisplatin' but not when treated in the opposite sequence. Therefore, when combination chemotherapy including cisplatin and vinca alkaloids is given, possible antagonism between them should be considered, especially in determining the schedule of drug administration.
Combinations of cisplatin and one of the vinca alkaloids have been shown to have marked activity against a wide variety of clinically encountered neoplasms (Einhorn & Donohue, 1977; Spaulding et al., 1980; Gralla et al., 1981; Kelsen et al., 1982) . However, little is known about the pharmacological interactions between cisplatin and vinca alkaloids. In this study, we demonstrate that cisplatin antagonises the cytotoxic effects of vinca alkaloids against human tumour cells in vitro and that the antagonism between them is dependent on the schedule of drug administration. These results demonstrate the importance of properly scheduling drug administration when employing a combination of cisplatin and vinca alkaloids.
Materials and methods
Cells and reagents A549 lung cancer cells were obtained from Dr Michael B. Sporn, HT29 colon cancer cells from Dr Nobuhiko Tanigawa and A431 epidermoid carcinoma cells from Japan Cancer Research Resource Bank. These three cell lines and NC65 renal carcinoma cells (Hoehn & Schroeder, 1978) were grown in a humidified 5% CO2 atmosphere at 37°C using Dulbecco's modification of Eagle's medium supplemented with 10% fetal calf serum. The same culture conditions and culture medium were used throughout this study. Drug solutions were made freshly for each experiment.
Monolayer assays Simultaneous exposure. In this study, cells were treated with cisplatin and one of other cytotoxic agents simultaneously and continuously unless otherwise indicated. Some 5 x 104 cells were plated in the wells of 24-well culture plates and cultured overnight. Then the combinations of serial two-fold dilutions of cytotoxic agents were added in chequer-board fashion (Sande & Mandell, 1985) . After cells were cultured for 3 days in the presence of drugs, cellular survival was determined as previously described (Sugarman et al., 1985) . In brief, at the termination of cultures, cells were fixed and stained with 0.5% crystal violet/20% methanol and the amounts of the dye that had stained the cells were measured by absorbance at 540 nm after elution into 0. Soft agar assays Some 3 x 103 cells in 1 ml 0.3% agar were plated over underlayers of 1 ml 0.5% agar containing specified amounts of combined cytotoxic agents prepared in 35 mm Petri dishes. After cells were cultured for 10 days, they were stained with 0.1% 2-(p-iodophenyl)-3-(p-nitrophenyl)-5-phenyl tetrazolium chloride (INT) (Alley et al., 1982) . Cell clusters larger than 60 jM were counted as colonies using an inverted microscope. The percentage survival was defined as colonies(drugs)/colonies(control) X 100 (%).
Results
The cytotoxic effects of cisplatin on A549 cells were assessed with the monolayer assay described above in five separate experiments in order to evaluate the validity of the assay system ( Figure 1 ). The intra-assay variations were less than 10% in each of five experiments and interassay variations among those five experiments were less than 20%.
The cytotoxic effects of adriamycin, 5-fluorouracil (5FU), etoposide, 1-p-D-arabinofuranosylcytosine (Ara C) and mitomycin C (MMC) against A549 lung cancer cells in monolayer cultures were enhanced by combinations with cisplatin, as shown in Figure 2 . The dose-response curves of these agents shifted downwards parallel to the increasing doses of cisplatin. As illustrated by the isobologram for the 75% inhibitory dose (ID75) of the combination of cisplatin and MMC demonstrated in Figure 2 , isobologram analysis (Sande & Mandell, 1985) based on these dose-response curves showed additivism between cisplatin and these five cytotoxic agents. In contrast, the cytotoxic effects of vincristine, vindesine, vinblastine and podophyllotoxin against A549 cells were antagonised by cisplatin (Figures 3 and 4) . The slopes of the dose-response curves of three vincas and podophyllotoxin ANTAGONISM BETWEEN CISPLATIN AND VINCAS 37 Cisplatin (,ug ml1-) 0 125 25 5 r .
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The antagonistic effects of cisplatin on the cytotoxicity of vincristine on A549 cells were also observed with a soft agar colony assay ( Figure 5 ). Less colony inhibition was achieved by the combination of cisplatin and vincristine than by vincristine alone when the concentrations of vincristine exceeded 125 ng ml -1. The antagonism between cisplatin and vincristine was not specific for A549 cells. Cisplatin also decreased the cytotoxic effects of vincristine on HT29 colon cancer cells, NC65 renal carcinoma cells and A43 1 epidermoid carcinoma cells ( Figure 6 ).
The interaction between cisplatin and vincristine was dependent on the sequence of their administration ( Figure  7) . When A549 cells were exposed for 6 hours to either of these agents sequentially, the antagonism between them was observed only when cells were pretreated with cisplatin. Although the dose-response curves of vincristine shifted downwards in parallel with increasing doses of cisplatin when cells were first treated with vincristine, they became flat, as in the case with continuous and simultaneous exposure, when cells were exposed to these agents in the opposite sequence. Figure 3 ). It should be noted that isobols could not be specified for these combinations because of the flattening of the dose-response curves.
In (Figure 2 ), phase-specificity of vincas and podophyllotoxin does not fully explain the antagonism with cisplatin. Whether or not the alterations of cell cycle kinetics could play a role in this antagonism awaits further definitive studies, including the flow cytometric analysis of the cell cycle of cells under treatment with combinations of cisplatin and various phase-specific agents.
Another possible explanation for the antagonistic interaction between them is that cisplatin interferes with the major action site of vinca alkaloids and podophyllotoxin, i.e. inhibition of polymerisation of microtubules. While the cytotoxic effect of cisplatin is thought to be exerted by its aqueous form through the formation of cross-linking of DNA chains (Rosenberg, 1985) , hydrolysed cisplatin has also been shown to inhibit microtubule polymerisation, although it is not clear whether hydrolysed cisplatin reacts with tubulin or microtubule-associated proteins (Peyrot et al., 1983) . In addition, peripheral neuropathy, a side effect common to vincas, has also been reported for cisplatin (Reinstein et al., 1980; Cowan et al., 1980) . If cisplatin antagonises the effects of vincas by blocking their major action site, prior exposure of cells to cisplatin could result in more marked antagonism than when cisplatin follows the vincas; and this was the case with the interaction between cisplatin and vincristine on A549 cells (Figure 7) . Moreover, Cells were cultured and stained as described in Materials and methods.
it should be noted that while the cytotoxic effects of podophyllotoxin on A549 cells were antagonised by cisplatin, those of etoposide, a derivative of podophyllotoxin, were shown to be additive to cisplatin (Figures 2 and 3 ). As etoposide neither binds to tubulin nor prevents microtubule polymerisation (Krishan et al., 1975; Loike & Horwitz, 1976) , only tubulin-binding agents may be specifically antagonised by cisplatin. Contrary to the results of our in vitro experiments, combinations of cisplatin and vincas have been shown to produce significantly higher response rates against a wide variety of clinically encountered neoplasms than when each agent is used alone (Einhorn & Donohue, 1977; Spaulding et al., 1980; Gralla et al., 1981; Kelsen et al., 1982 0) 
